Cargando...
Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
BACKGROUND: Aberrant progesterone/receptor activator of nuclear factor κβ (RANK) signaling has been implicated in BRCA1 breast cancer development. Furthermore, lower circulating RANKL has been reported among women with a BRCA mutation compared to non-carriers; however, there have been no reports of...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6497430/ https://ncbi.nlm.nih.gov/pubmed/31069010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26810 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|